Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]
, 2011 Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V +8 more
core +1 more source
Primary Non-Hodgkin Lymphoma of The Cervix [PDF]
International Journal of Hematology-Oncology and Stem Cell Research, 2011 Background: There are only a few reports that exist regarding primary non-Hodgkin lymphoma of the genital tract. In this article, one case of primary B-cell type non-Hodgkin lymphoma (NHL) of the cervix is presented.
Haleh Ayatollahi +2 more
doaj +2 more sources
Human leukocyte antigens and genetic susceptibility to lymphoma [PDF]
, 2015 Familial aggregation, coupled with ethnic variation in incidence, suggests that inherited susceptibility plays a role in the development of lymphoma, and the search for genetic risk factors has highlighted the contribution of the human leukocyte antigen (
Jarrett, R.F., McAulay, K.A.
core +1 more source
Lymphohaematopoietic malignancies in Scottish military veterans: Retrospective cohort study of 57,000 veterans and 173,000 non-veterans [PDF]
, 2017 Background: Lymphohaematopoietic malignancies are common in the general population. There have been concerns that military service may be associated with increased risk as a result of occupational exposures.
Bergman, Beverly P. +2 more
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
Association of group erythrocyte antigens and B-cell non-Hodgkin lymphoma
Regulatory Mechanisms in Biosystems, 2016 We analyzed the frequency distribution of blood groups AB0, Rhesus and Kell in patients with B-cell non-Hodgkin lymphoma. An increase of D− patients (31.0%) among ill in comparison to healthy individuals (16.5%) was found.
U. V. Tymoshenko +4 more
doaj +1 more source
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper [PDF]
, 2016 Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian ...
Barosi, Giovanni +7 more
core +1 more source
BMJ, 2018 The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising from cells of the immune system and manifesting predominantly as lymphadenopathy or solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 different subtypes listed in the latest WHO classification of lymphoma (1).
Bowzyk Al-Naeeb, Anna +3 more
openaire +3 more sources
Gastric cancer is the leading cause of death in Italian adult patients with common variable immunodeficiency [PDF]
, 2018 An increased prevalence of malignant lymphoma and of gastric cancer has been observed in large cohorts of patients with common variable immunodeficiency (CVID), the most frequently symptomatic primary immunodeficiency. Surveillance strategies for cancers
Agostini, Carlo +11 more
core +3 more sources
BMC Oral Health, 2022 Background Little is known about the epidemiology of lymphomas occurring in oral and para-oral sites, especially in developing countries such as Egypt.
Madiha Ashoub +5 more
doaj +1 more source